Inhalation April 2022 41
• EPA to Reexamine Health Stan-
dards for Harmful Soot that
Previous Administration Left
Unchanged, June 10, 2021,
https://www.epa.gov/news
releases/epa-reexamine- health-
s t a n d a r d s - h a r m f u l - s o o t -
previous-administration-left-
unchanged.
•
Even Low Levels of Soot
Can be Deadly to Older Peo-
ple Research Finds, e New
Yo r k Ti m e s , Ja n u a r y 2 7 ,
2022, https://www.nytimes.
com/2022/01/26/climate/air-
pollution-study-epa.html.
As part of this process, the EPA
explained, "it will develop a supple-
ment to the 2019 Final Integrated
Science Assessment (ISA) that will
take into account the most up-to-
date science, including new studies
in the emerging area of COVID-
related research." In addition, in
accordance with Executive Orders
and guidance, the agency will be
considering environmental justice
during the rulemaking process."
"Importantly, results of this study
will be able to inform the EPA as to
whether or not they should lower
the National Ambient Air Quality
Standards for PM
2.5
in the United
States," Dominici told e New
York Times.
e EPA is expected to propose a
draft rule by the summer of 2022
and issue a final rule by the spring
of 2023.
References
Content for this article was based
on and excerpted from:
•
Ne w U . S . St u d y Re p o r t s
Health Effects At Air Pollution
Levels Below Current Stan-
dards, Health Effects Institute,
January 26, 2022, https://
www.healtheffects.org/system/
files/dominici-rr-211-press_
release_1.pdf.
• Assessing Adverse Health Effects
of Long-Term Exposure to Low
Levels of Ambient Air Pollution,
Synopsis of Research Report
211, Health Effects Institute,
January 2022, https://www.
healtheffects.org/system/files/
dominici-rr-211-statement.pdf.
• Dominici F, Zanobetti A,
Schwartz J, et al., Assessing
Adverse Health Effects of Long-
Term Exposure to Low Levels of
Ambient Air Pollution: Imple-
mentation of Casual Inference
Methods, Health Effects Insti-
tute, Research Report 211,
January 2022, https://www.
healtheffects.org/system/files/
dominici-rr-211-report_1.pdf.
Trusted, Reliable Contract
Development & Manufacturing
renpharm.com
R&D Services
– Formulation – Scale-up – Stability
– 2-100 mL vials – 2-100 mL vials
Injectables
– Multi-Dose – Unit Dose – Bi-Dose Multi-Dose – Unit Dose – Bi-Dose
Nasal
Renaissance develops and manufactures high-quality
pharmaceuticals to fulfill your patients' needs.
